A Philadelphia biotechnology company founded seven years ago by two former Johnson & Johnson executives has a new leader.

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class ...

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 ...

BOTHELL, Wash. - Immunome, Inc. (NASDAQ:IMNM), a biotechnology firm engaged in the development of targeted cancer therapies, revealed plans for a public offering of $125 million in common stock.

Dr. Yuzhong Liu, an assistant chemistry professor at Scripps Research, was among three scientists granted $150,000 Wednesday ...

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 3 ...

Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Varegacestat offers potential advantages, such as once-daily dosing, over SWTX's ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on IMNM: Immunome NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its ...